The activation of the PI3K/Akt/mTOR pathway has been found to be associated with the histologic malignancy and tumor progression of myxofibrosarcoma, and the PI3K/Akt/mTOR pathway has the potential to be a therapeutic target for primary and recurrent myxofibrosarcomas, but no PIK3CA mutation was found in their study (32). The gene discussed is MTOR; the disease is myxofibrosarcoma.